|
Study Title
|
N
|
Study Type
|
Sponsor
|
Status
|
Ref
|
|
High-dose MTX and
deferred radiation therapy for PCNSL
|
|
II
|
NCI/NABTT
|
Closed, 1999
|
1
|
|
MTX and thio-TEPA for PCNSL
|
|
II
|
NCI/NABTT
|
Open, 2002
|
2
|
|
NOA-03 trial of high-dose
MTX for PCNSL
|
|
II
|
NOA
|
Closed, 2000
|
3
|
|
First-line temozolomide therapy for PCNSL patients
|
|
II
|
none
|
Open, 2003
|
4
|
|
Primary CNS Lymphoma,
initial chemotherapy, followed by radiotherapy,
a phase II study, 1991-1995
|
33
|
II
|
none
|
Closed, 1995
|
5,6
|
|
CLMIT-1: Salvage therapy
with the new alkylating agent temozolomide
in
immunocompetent patients with primary CNS
lymphomas
|
24 of 38
|
II
|
|
Open, 2000
|
7
|
|
CLIMT-2: Primary
chemotherapy with high-dose methotrexate, cytarabine, thiotepa,
and idarubicin (MATILde
regimen) followed by response-modulated radiotherapy
for primary CNS lymphoma in immunocompetent
patients
|
36 of 42
|
II
|
|
Open, 2000
|
8
|
|
IELSG #20 (or CLIMT-3)
Randomized phase II trial on primary chemotherapy
with HD-MTX, alone or associated with high-dose cytarabine,
followed by response- and age-tailored radiotherapy for immunocompetent
patients with newly diagnosed primary CNS lymphoma
|
0 of 39 (x2)
|
R II
|
IELSG
|
Open, 2003
|
|
|
IELSG #21 (or CLIMT-4)
Salvage therapy with idarubicin in immunocompetent
patients with relapsed or refractory primary CNS lymphomas
|
0 of 25
|
II
|
IELSG
|
Open, 2003
|
|
|
Combination Chemotherapy
with Methotrexate, Cytoxan
and Etoposide Phosphate
in Conjunction with Osmotic Blood Brain Barrier Disruption (BBBD)
in Patients with Brain Malignancies
|
82
|
II
|
|
Closed May, 2000
|
9,10,11,12
|
|
Protocol A: Combination
Chemotherapy (Methotrexate, Procarbazine,
and CCNU),
Intraventricular Cytarabine
and Methotrexate, +/- Intra-Ocular Chemotherapy
for Patients with
Primary Central Nervous System Lymphoma (PCNSL)
|
180
|
II
|
|
Open May, 2000
|
13
|
|
Protocol B: Combination
Chemotherapy (Methotrexate, Cyclophosphamide,
and
Etoposide Phosphate) Delivered in Conjunction
with Osmotic Blood Brain Barrier Disruption (BBBD),
with Intraventricular Cytarabine
+/- Intra-Ocular Chemotherapy, in Patients with
Primary Central Nervous System Lymphoma
|
90
|
II
|
|
Open May, 2000
|
14
|
|
Phase II Study for
Patients with Relapsed Primary Central Nervous System Lymphoma
|
25
|
II
|
NIH/NINDS
|
Open April, 2003
|
15
|
|
90Y Ibritumomab
Tiuxetan Radioimmunotherapy
for Patients with Relapsed or
Recurrent Primary Central Nervous System Lymphoma
|
TBD
|
I/II
|
NIH/NINDS
|
Under Development
(May, 2003)
|
16
|
|
MTX and thio-TEPA for PCNSL
|
23-39
|
II
|
NCI/NABTT
|
Open, 2002
|
17
|
|
Intravenous methotrexate and cranial irradiation in the treatment
of PCNSL
|
46
|
II
|
TROG
|
Closed, 1997
|
18
|
|
A phase II study of Idarubicin based combined modality therapy in PCNSL
|
Target 53
|
II
|
TROG
|
Open, 2001
|
19
|
|
High-dose methotrexate for primary CNS lymphoma in the elderly
|
10
|
II
|
|
Closed
|
20
|
|
MTX and thio-TEPA for PCNSL
|
23-39
|
II
|
NCI/NABTT
|
Open, 2002
|
21
|
|
Combined Immunochemotherapy with Reduced dose RT for newly
diagnosed PCNSL
|
15-30
|
II
|
MSKCC
|
Open, 2002
|
22
|
|
High dose MTX and AraC followed by myeloablative
BEAM chemotherapy.
|
28
|
II
|
MSKCC
|
Closed, 2000
|
23
|
|
MTX, procarbazine
and vincristine with or without WBRT
|
56
|
II
|
MSKCC
|
Closed, 1998
|
24
|
|
Multicenter trial of single-agent HD-MTX for primary central
nervous system lymphoma (NOA-03)
|
37
|
II
|
|
Closed 5/2000
|
25
|
|
Multicenter BMPD study for primary CNS lymphoma
|
56
|
III
|
|
Closed 5/2000
|
*
|
|
HD-Chemotherapy with autologous hematopoietic stem
cell transplantation and
response-adapted radiotherapy (OSHO-53)
|
13
|
II
|
|
Open, June 2003
|
26
|
|
HD-MTX followed by dose-escalated
alkylating agents with autologous
PBSCT and
hyperfractionated radiotherapy as
first-line treatment for primary CNS lymphoma
|
ca. 30
|
II
|
|
Open, June 2003
|
27,28
|
|
Combined systemic and intraventricular chemotherapy in primary CNS lymphoma
|
Ca. 60
|
II
|
|
Open, June 2003
|
29,30
|
|
Phase IV study on the
role of whole brain irradiation in primary CNS lymphoma (PCNSL)
with HD-MTX (G-PCNSL-SG1)
|
Ca. 200
|
IV
|
German
Cancer Society
|
Open, June 2003
|
31
|
|
High-Dose Methotrexate-Based Chemotherapy Followed by
Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous
System Lymphoma: Phase II Trial 20962
|
|
II
|
|
|
32
|
|
Intensive methotrexate and cytarabine
followed by high-dose chemotherapy with autologous
stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an
intent-to-treat analysis.
|
|
|
|
|
33
|
|
Chemotherapy alone as initial
treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952)
|
|
II
|
European Organization for
Research and Treatment of Cancer Brain Tumor Group.
|
|
34
|
|
Primary Central Nervous System
Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred
Radiotherapy.
|
|
|
|
|
35
|
|
|
|
|
|
*Publication Forthcoming
|
|
